Ventas Stock - Raymond James lifts rating to Moderate Buy
18.06.2026 - 16:56:12 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/18/2026, 16:54 CET. Details in the imprint.
Ventas (US92276F1003) stock is back on analyst radar after Raymond James raised its stance to Moderate Buy and set a new price target, according to a recent analyst update summarized by MarketBeat. The call adds to an already supportive Street view on the healthcare-focused REIT.
All news and analysis on Ventas stock
Key ratings, targets and filings on Ventas are bundled in our topic section alongside price data and further corporate news.
Raymond James raises its view
According to a MarketBeat note dated 06/18/2026, Raymond James has upgraded its rating on Ventas from a more neutral stance to Moderate Buy and set a price target around $94 per share. The MarketBeat analyst summary highlights the change. The move reflects a more constructive view on the REIT’s earnings prospects and balance sheet.
In a separate item, MarketBeat also reported that Bamco Inc. NY recently boosted its stake in Ventas, indicating continued institutional interest. The holding increase was disclosed via a regulatory filing summary. Taken together, the rating change and ownership shift underline that large investors remain engaged with the name.
What the analyst consensus shows
Across the Street, Ventas carries a consensus rating of "Moderate Buy" or "Buy" and an average price target in the mid-to-high $90s, based on compiled data from MarketBeat and MarketScreener. MarketScreener currently cites an average target near $96.90. That sits meaningfully above the low-$80s level where the shares last closed.
Some houses have adjusted their targets recently. Scotiabank, for example, trimmed its objective from $95 to $88 while maintaining a Sector Perform rating, signaling a more measured stance but not a fundamental break with the positive long-term thesis. Such mixed adjustments result in a balanced but broadly supportive consensus picture.
The product behind the stock
Ventas generates its cash flows primarily from a diversified portfolio of senior housing, medical office buildings, outpatient facilities and other healthcare real estate assets across North America. As a healthcare REIT, it focuses on long-term leases and demographic-driven demand rather than short-duration, cyclical tenants.
Where the stock trades today
The shares of Ventas (US92276F1003) trade on the New York Stock Exchange at about $82.15 as of 06/18/2026, 16:30 CET, implying a market capitalization near $36.8 billion in recent statistics.
Key facts on Ventas stock
- Company: Ventas, Inc.
- ISIN: US92276F1003
- WKN: 893484
- Ticker: VTR
- Venue: NYSE
- Price (as of 06/18/2026, 16:30 CET): 82.15 USD
- Market cap: 36.78 billion USD (as of 06/18/2026)
- Sector / Industry: Real Estate - Specialized REITs (Healthcare)
- Index membership: S&P 500
- Next earnings date: 02/05/2026 (after market close, per latest listing)
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
